...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in allergy and clinical immunology >Update of growth effects of inhaled and intranasal corticosteroids.
【24h】

Update of growth effects of inhaled and intranasal corticosteroids.

机译：吸入和鼻内皮质类固醇的生长作用更新。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A small effect (approximately 1 cm) of inhaled and intranasal corticosteroids on the 1 year growth of children with asthma and allergic rhinitis, respectively, has been reported in studies published during the past 10 years. Literature published during the past year confirmed the effect, but provided additional and novel information on the effects of longer-term (over 1 year) treatment, particularly with inhaled corticosteroids. This information is timely, because the longer-term effect size and duration were previously unknown, and the findings have major implications for the content of the safety discussion between caregivers and the parents of children with asthma or allergic rhinitis. The results of these studies provide very reassuring information about the longer-term safety of the use of inhaled corticosteroids in children with asthma. Limited evidence has also supported the notion that intranasal corticosteroids have no longer-term effects on growth. The possibility of an idiosyncratic (versus global) effect received conflicting support in recent literature. The risk of growth retardation can be lessened and managed by the employment of several simple strategies: (i) monitor growth; (ii) use minimal effective dose; and (iii) optimize steroid-sparing strategies. Communication with patients/parents about this possible side-effect, as well as the adverse consequences of the non-use of inhaled and intranasal corticosteroids, is essential to minimize any possible negative impact on adherence. Children whose disease severity warrants inhaled or intranasal corticosteroid therapy should not be denied their benefits on the basis of this safety consideration.
机译：过去10年间发表的研究报告了吸入性和鼻内皮质类固醇分别对哮喘和变应性鼻炎患儿1年生长产生小的影响（约1 cm）。过去一年中发表的文献证实了这种作用，但提供了关于长期（超过1年）治疗（尤其是吸入皮质类固醇激素）的影响的新信息。该信息是及时的，因为长期的影响大小和持续时间以前是未知的，并且该发现对看护人与哮喘或过敏性鼻炎儿童的父母之间的安全性讨论内容具有重要意义。这些研究结果为哮喘儿童吸入皮质类固醇的长期安全性提供了非常令人放心的信息。有限的证据也支持鼻内皮质类固醇对生长没有长期影响的观点。在最近的文献中，特质（相对于全球）效应的可能性得到了相互矛盾的支持。可以通过以下几种简单的策略来降低和控制增长迟缓的风险：（i）监控增长; （ii）使用最小有效剂量; （iii）优化保存类固醇的策略。与患者/父母就这种可能的副作用以及不使用吸入和鼻内使用皮质类固醇的不良后果进行沟通，对于最大程度地减少对依从性的负面影响至关重要。出于安全考虑，不应拒绝疾病严重程度需要吸入或鼻内糖皮质激素治疗的儿童。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号